SUSTAINED-RELEASE STING AGONIST IMPLANTS ACTIVATE ANTITUMOR IMMUNITY TO TREAT ADVANCED BREAST CANCER IN COMBINATION WITH PARPI
$1,327,332FY2025Defense Health AgencyDOD
Brigham & Womens Hospital Inc
Investigators
View source on USAspending →SUSTAINED-RELEASE STING AGONIST IMPLANTS ACTIVATE ANTITUMOR IMMUNITY TO TREAT ADVANCED BREAST CANCER IN COMBINATION WITH PARPI · GrantIndex